Scientists recommend wider use of clot-busting stroke drug

09/25/2008 | Wall Street Journal, The

A stroke drug from Genentech called tissue plasminogen activator, marketed as Activase in the U.S., can be administered 4 1/2 hours after the onset of stroke symptoms -- past the three-hour limit recommended by the FDA -- a study concluded. Researchers found that 52% of patients who received TPA more than three hours after suffering a stroke survived with little impairment based on the Rankin scale while the rate for those who got placebo was 45%. The study was conducted in Europe by Boehringer Ingelheim, Genentech's business partner.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL